CONSORT Guidelines Simplified for Trial Reporting

A randomized trial can be flawlessly designed and still fail its readers if the published report leaves out how randomization was concealed, how many participants dropped out, or why the trial stopped early. CONSORT guidelines exist to close that gap. Consolidated Standards of Reporting Trials, the checklist’s full name, gives authors a minimum set of items to disclose so that peer reviewers, clinicians, and systematic reviewers can judge a trial on what actually happened rather than on a polished summary of it. Editverse works with trial authors preparing manuscripts for journals that require CONSORT compliance, and the guidance changed substantially in April 2025, the first rewrite since 2010. What follows works through what the update means, how the checklist is now structured, and what a compliant trial report needs to include.

What Are CONSORT Guidelines, and Why Trials Need Them

Peer reviewers cannot evaluate a trial they cannot fully see. That’s the problem CONSORT was built to solve. A group of trialists, statisticians, and journal editors first published the CONSORT statement in JAMA in 1996, after research had repeatedly shown that published trial reports omitted details needed to judge whether a result was trustworthy, missing information on allocation concealment, blinding, or how dropouts were handled. Revisions followed in 2001 and again in 2010, each version tightening the list based on evidence about which omissions actually correlated with biased results.

CONSORT is not a style guide. It’s a minimum reporting standard, a checklist plus a participant flow diagram that authors work through before submission, built for parallel-group randomized controlled trials. Journals that follow the ICMJE recommendations, which includes most major medical and clinical journals, require or strongly encourage CONSORT-compliant reporting. Editors use it during peer review, and systematic reviewers use it to judge whether a trial’s methods section gives them enough detail to include the study in a meta-analysis with confidence.

CONSORT 2025: The Guidelines Just Got Their Biggest Update Since 2010

For fifteen years, CONSORT meant the 2010 checklist, 25 items organized under title, introduction, methods, results, and discussion. That changed on April 14, 2025, when Hopewell and colleagues published the CONSORT 2025 statement simultaneously in The BMJ, JAMA, The Lancet, Nature Medicine, and PLOS Medicine, an unusually coordinated release meant to reach clinical researchers wherever they publish.¹ If a manuscript, course syllabus, or older guide is still walking through the 25-item list as current, it’s describing a superseded version.

Seven items are new, three were revised, and one was dropped, the standalone generalisability item, now folded into the discussion of trial limitations. Item count has grown to 30, concentrated in three areas that reviewers kept flagging as gaps in the 2010 version. Trial registries and open science practices earned their own new section, sitting right after the abstract, covering trial registration, the location of the protocol and statistical analysis plan, whether individual participant data will be shared, and a fuller conflict-of-interest disclosure for every author, not just the corresponding one. Patient and public involvement in designing or running the trial now needs its own line, reflecting how routine that involvement has become in funded research. Harms reporting was strengthened throughout, matching recommendations that had circulated as a separate CONSORT extension for years, and the results section now asks authors to spell out how missing data were handled and which population, the full randomized set or a defined subset, each reported result actually used.

A companion explanation and elaboration paper runs through the reasoning behind each item, with examples of good and weak reporting drawn from published trials.² It’s a useful reference for anyone drafting a submission, not only for reviewers checking compliance. A parallel rewrite, SPIRIT 2025, updates the matching checklist for trial protocols, so the guidance now runs from the protocol stage through to the final report using shared vocabulary.³

The CONSORT 2025 Checklist, Section by Section

The clearest way to see what changed is to look at how the checklist is now organized. Six sections structure the 30 items, and the new Open Science section is the one most likely to catch out authors still working from an old template.

Authors used to treating CONSORT as a methods-section checklist will notice the shift. Open science reporting now sits near the top of the paper, right where a reader looks first, rather than scattered across acknowledgments and a data availability statement tacked on at the end.

The CONSORT Flow Diagram Still Matters

Most of the attention goes to the checklist, but CONSORT has always paired it with a flow diagram, and that requirement hasn’t gone anywhere in the 2025 update. The diagram tracks participants through several stages, from those assessed for eligibility, through allocation to a study group, through follow-up, to the number actually analyzed. Reviewers use it as a quick sanity check. If the analyzed count in the text doesn’t match the number in the diagram’s final box, or a large share of participants disappears between allocation and analysis with no explanation, that mismatch tends to be the first thing a statistical reviewer flags.

A well-built diagram also does something prose can’t do as efficiently, showing exclusions and losses at each stage side by side, so a reader sees at a glance whether attrition was balanced between arms or concentrated in one, which matters directly for how the intention-to-treat and per-protocol estimates compare against each other.

CONSORT Extensions for Specialized Trial Types

Most trials don’t match the two-arm, parallel-group drug trial the core checklist assumes. To cover the gap, the CONSORT Group has published extensions, each one adapting the base 30 items to a specific design or intervention rather than replacing them.

Pilot and feasibility trials received their own extension in 2016, because the goal of a pilot isn’t to show an effect but to test whether a full-scale trial is workable, so the reporting priorities shift toward recruitment rates, protocol adherence, and progression criteria rather than efficacy.⁴ Non-pharmacologic treatments such as surgery, physical therapy, or behavioral interventions carry their own 2017 update, since blinding, standardizing the intervention, and describing the skill of whoever delivers the treatment raise different questions than they do for a pill.⁵ The newest addition covers trials of interventions built on artificial intelligence, known as CONSORT-AI, which asks authors to report the AI system’s version, how it was integrated into clinical workflow, and how it performed outside the setting it was trained in, questions a conventional drug trial checklist never anticipated.⁶

Beyond those three, the EQUATOR Network’s CONSORT page lists extensions for cluster-randomized trials, crossover designs, non-inferiority and equivalence trials, patient-reported outcomes, and several other specialized designs. Anyone running a trial that doesn’t fit the standard parallel-group mold should check that list before drafting the methods section. Using the wrong checklist is a common reason a submission comes back with a request to revise reporting rather than a substantive scientific critique, and Editverse’s trial design consultation often starts with exactly this kind of mismatch.

Do CONSORT Guidelines Actually Improve Trial Reporting?

Adopting a checklist only matters if it changes what gets published, and that question has been tested directly. Moher and colleagues compared trial reports in medical journals before and after those journals adopted the CONSORT statement, and found that adopting journals showed measurably better reporting of allocation concealment and sample size calculations than journals that hadn’t endorsed it.⁷ A later systematic review pooling multiple before-and-after and comparative studies reached a similar conclusion: reporting quality improved after CONSORT adoption across most of the studies reviewed, though the size of the improvement varied by journal and by which checklist item was being measured.⁸ Kane and colleagues, looking specifically at attrition reporting in major journals, found the same pattern. Reports grew more complete once CONSORT became an editorial requirement rather than a suggestion.⁹

None of this means CONSORT adoption alone guarantees a well-reported trial. Field-specific audits, from otolaryngology to palliative care, have kept finding gaps years after journals required the checklist, usually in the same handful of items: missing data handling, the method of allocation concealment, and precise definitions of the primary outcome. Writing the actual sentence is still on the author, not the checklist, and journals catch incomplete CONSORT compliance often enough that treating it as a final proofreading step, rather than a drafting guide from the start, remains a common and avoidable mistake.

How to Apply CONSORT Guidelines When Writing Your Trial Report

Working through CONSORT in the right order saves rework later, and the sequence below follows how the checklist maps onto the drafting process, from protocol through to the finished manuscript.

1. Start from the protocol, not the results. Registration details, the statistical analysis plan, and the eligibility criteria should already exist before drafting begins. Retrofitting these into a finished manuscript is where the most obvious gaps show up.
2. Draft the flow diagram before the results section. Counting participants at each stage early exposes discrepancies while they’re still easy to trace back to source data.
3. Write the methods section against the checklist directly, item by item, rather than from memory. Randomization method, allocation concealment, and blinding are the items reviewers check first and the ones most often left vague.
4. Define every analysis population before reporting a single result. State plainly whether a given table uses the full randomized set, a modified intention-to-treat population, or a per-protocol subset, and keep that definition consistent throughout.
5. Report harms with the same rigor as efficacy outcomes. A short note that “no serious adverse events occurred,” with no description of how harms were monitored, no longer meets the 2025 standard.
6. Complete the Open Science items last, right before submission. Data sharing statements and conflict-of-interest disclosures depend on what actually happened during the trial and are easy to get out of sync if drafted too early.
7. Check the manuscript against the relevant extension if the trial is a pilot study, a non-drug intervention, a cluster design, or involves an AI system, since the base 30 items won’t capture everything reviewers expect.

Common CONSORT Reporting Gaps to Watch For

A handful of gaps come up often enough in editorial and statistical review to call out directly.

Sample size justification frequently shrinks to a single sentence citing an effect size with no source, when reviewers expect the assumptions, the target power, and the calculation itself to be traceable. Power analysis done properly at the design stage makes this section easy to write later. Done as an afterthought, it rarely survives review unchanged.

Confusion between intention-to-treat and per-protocol populations is another recurring issue, particularly when a paper labels an analysis “ITT” but has quietly excluded participants who never received treatment. That’s a modified ITT population, not a true ITT population, and CONSORT 2025 expects the distinction to be stated plainly. A closer look at how these populations diverge shows why the labeling matters for how a result gets interpreted downstream.

Missing data handling is the item most likely to be reported vaguely even in otherwise well-written manuscripts. Stating that missing values “were imputed,” without naming the method, the assumptions behind it, or how much data was actually missing, leaves reviewers unable to judge whether the approach could have shifted the result. Documenting the missing-data strategy properly at the analysis stage avoids a late rewrite.

Trial registration numbers, when present, sometimes don’t match what was actually done. A primary outcome registered before the trial started occasionally gets swapped for a more favorable one by the time of publication. CONSORT 2025’s expanded Open Science section makes that kind of outcome switching easier for reviewers and readers to catch, which is precisely the point.

CONSORT, STROBE, and PRISMA: Which Guideline Fits Your Study

CONSORT is only the right tool for randomized trials. Researchers reporting other study types need a different checklist, and mixing them up is a fast way to get a manuscript sent back before it reaches peer review.

Observational research, cohort, case-control, and cross-sectional studies, follows STROBE, the Strengthening the Reporting of Observational Studies in Epidemiology statement, which covers similar ground (design, participants, variables, results) but replaces items like randomization and blinding with confounding and bias considerations specific to non-randomized designs. Systematic reviews and meta-analyses follow PRISMA instead, built around a different flow diagram, one that tracks records identified, screened, and included rather than participants randomized and followed up. Editverse has a step-by-step guide to building a PRISMA flow chart for researchers working on a systematic review, and the common mistakes that show up in meta-analyses are worth reviewing alongside it.

Across all three guidelines, the underlying logic stays the same. Each one asks authors to report enough methodological detail that a skeptical reader could evaluate, and in principle reproduce, what was actually done. Picking the right one for a given study design is the first decision, not an afterthought.

How Editverse Supports CONSORT-Compliant Trial Reporting

Getting a trial report through peer review on the first attempt usually comes down to whether the methods and results sections were built against CONSORT from the start, not patched to match it after a reviewer complains. Editverse’s clinical research team works with trial authors at both stages.

• Checking a completed draft against the current CONSORT 2025 checklist and flagging specific missing items before submission
• Building or auditing the participant flow diagram against the numbers reported in the results text
• Trial design consultation for studies that need a CONSORT extension, including pilot trials, cluster designs, and non-pharmacologic interventions
• Protocol and statistical analysis plan documentation aligned with SPIRIT 2025, so the eventual trial report and the registered protocol match

Frequently Asked Questions About CONSORT Guidelines

What does CONSORT stand for?

Consolidated Standards of Reporting Trials. It’s a checklist and flow diagram for reporting the results of randomized controlled trials, first published in 1996 and most recently updated in April 2025.

Is CONSORT 2010 still valid, or must I use CONSORT 2025?

CONSORT 2025 replaces the 2010 version. Journals are moving to reference the current statement, and a manuscript built against the older 25-item checklist will be missing several items reviewers now expect, particularly around data sharing, patient involvement, and harms reporting.

How many items are in the CONSORT 2025 checklist?

Thirty, organized across six sections including a new Open Science section. CONSORT 2010 had 25 items and no separate open science category.

Does CONSORT apply to pilot studies or non-drug interventions?

The base checklist applies broadly, but pilot and feasibility trials, non-pharmacologic interventions, and AI-based interventions each have a dedicated CONSORT extension that adds or reframes items specific to that design.

What’s the difference between CONSORT and STROBE?

CONSORT covers randomized trials. STROBE covers observational studies, cohort, case-control, and cross-sectional designs, where there’s no randomization or blinding to report but confounding and selection bias need addressing instead.

What’s the difference between CONSORT and PRISMA?

CONSORT is for reporting a single randomized trial. PRISMA is for reporting a systematic review or meta-analysis that may pool results from many trials, and it uses a different flow diagram tracking records screened and studies included rather than participants randomized.

Do journals actually enforce CONSORT compliance?

Most major medical journals that follow ICMJE recommendations require or strongly encourage it for randomized trial submissions, and editors commonly send a manuscript back for CONSORT-specific revisions before it goes to full peer review.

Where can I find the official CONSORT 2025 checklist?

The full statement and checklist are freely available through the CONSORT website and the EQUATOR Network, along with the explanation and elaboration document and the full list of extensions.

References

1. Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025;389:e081123. doi:10.1136/bmj-2024-081123 PMID: 40228833
2. Hopewell S, Chan AW, Collins GS, et al. CONSORT 2025 explanation and elaboration: updated guideline for reporting randomised trials. BMJ. 2025;389:e081124. doi:10.1136/bmj-2024-081124 PMID: 40228832
3. Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, et al. SPIRIT 2025 statement: updated guideline for protocols of randomized trials. JAMA. 2025. doi:10.1001/jama.2025.4486 PMID: 40294593
4. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239. doi:10.1136/bmj.i5239 PMID: 27777223
5. Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT statement for randomized trials of nonpharmacologic treatments: a 2017 update. Ann Intern Med. 2017;167(1):40-47. doi:10.7326/M17-0046 PMID: 28630973
6. Liu X, Cruz Rivera S, Moher D, Calvert MJ, Denniston AK. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. Lancet Digit Health. 2021;3(1):e1-e5. doi:10.1016/S2589-7500(20)30218-1 PMID: 33328048
7. Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA. 2001;285(15):1992-1995. doi:10.1001/jama.285.15.1992 PMID: 11308436
8. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, et al. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust. 2006;185(5):263-267. doi:10.5694/j.1326-5377.2006.tb00557.x PMID: 16948622
9. Kane RL, Wang J, Garrard J. Reporting in randomized clinical trials improved after adoption of the CONSORT statement. J Clin Epidemiol. 2007;60(3):241-249. doi:10.1016/j.jclinepi.2006.06.016 PMID: 17292017
10. Begg C, Cho M, Eastwood S, Horton R, Moher D, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996;276(8):637-639. doi:10.1001/jama.276.8.637 PMID: 8773637

Editverse Research Team | Updated August 2026